Environmental Clean Technologies (ASX:ECT): PFAS is the “new asbestos” and the bill is coming due
On the 24th of December 2025, Environmental Clean Technologies (ASX:ECT) acquired the patent rights to Flash Joule Heating (FJH) technology for the remediation of PFAS in soil from Rice University. The technology was developed under Professor James Tour, who is widely recognised for pioneering this rapid heating method. ECT intends to deploy FJH to address one of the most significant environmental liabilities emerging globally, PFAS chemicals, a family of roughly 15,000 compounds often described as “forever chemicals” or the “new asbestos” due to their environmental persistence and health concerns.
PFAS spending is surging, but legacy solutions only move the problem
A core challenge in the PFAS remediation market is that spending is rising, while many legacy solutions remain structurally inefficient. In Australia and the United States, governments and industry are spending more than US$10 billion per year on contaminated site remediation, with budgets rising as standards tighten and more sites are identified. In the US, PFAS contamination is estimated to impact around 57,000 sites, while in Australia, approximately 1,700 sites have been identified. Traditional approaches, such as excavation and landfill, and many forms of soil washing, can be capital-intensive and expensive to operate at scale.
More importantly, they often do not destroy PFAS. Instead, they relocate the problem or contain it, leaving a long-dated liability that can re-emerge through monitoring costs, compliance risk, and future remediation obligations. Early lab work at Rice University indicates Flash Joule Heating, which underpins ECT’s technology, can destroy PFAS, including up to 99.98% removal of PFOA, one of the most prevalent PFAS compounds.
Valuation range of A$0.27 – A$0.34 per share
We valued ECT using a peer-weighted approach anchored to Metallium’s market capitalisation of A$445m, implying A$95m or A$0.27 per share in our base case and A$120m or A$0.34 per share in our bull case under normalised market conditions. ECT looks broadly comparable to where Metallium was valued in January 2025, before it re-rated as it moved from strong laboratory testing into early commercial traction. We think ECT is at a similar stage today. We expect ECT to re-rate over the next 6 to 12 months, supported by positive FJH testing results, technology optimisation, and potential collaborations with industrial machinery companies. This supports our valuation range of A$0.27 to A$0.34 per share.
